Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates - Featured image
GLP-1 Medications

Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·January 22, 2026·2 min read

On this page

  • The Breakthrough of Ozempic and GLP-1 Agonists
  • Serendipity in Scientific Discovery
  • Real-Life Transformations and Nuanced Perspectives
  • Societal and Cultural Context

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.

Share

On this page

  • The Breakthrough of Ozempic and GLP-1 Agonists
  • Serendipity in Scientific Discovery
  • Real-Life Transformations and Nuanced Perspectives
  • Societal and Cultural Context

In 2024, the US Centers for Disease Control and Prevention released data revealing a historic shift: American obesity rates slightly declined after decades of steady increase. Experts hail this as one of the most significant public health tables in modern history.

The Breakthrough of Ozempic and GLP-1 Agonists

Novo Nordisk launched Ozempic in 2017 as a diabetes medication, noting weight loss as a side effect. Developers anticipated this would become the primary benefit, and it has. These GLP-1 agonists, dubbed "fat drugs," are now reducing obesity rates across multiple regions.

Future developments promise even greater reach: oral pills instead of injections and generic versions post-patent expiration could amplify their impact dramatically.

Serendipity in Scientific Discovery

The story of weight-loss injections blends chance, competition, and dedication. Macedonian chemist Svetlana Mojsov pioneered GLP-1 research in the 1970s, identifying glucagon-like peptide's role in blood sugar regulation. Ozempic mimics this hormone to curb appetite and promote fullness.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play
  • Key discovery: A peptide from Gila monster lizard saliva proved instrumental.
  • Mojsov's work laid the foundation for modern GLP-1 therapies.

Societal and Cultural Context

These drugs spark debate amid intense social pressures. While medically essential for some, others seek them for aesthetic goals like fitting smaller clothes or meeting social media ideals.

Real-Life Transformations and Nuanced Perspectives

Patients report profound changes. A 34-year-old marketer named Sarah gained inclusion in key meetings and a promotion after losing weight on Ozempic.

Yet, the verdict remains balanced. Do GLP-1 drugs treat symptoms rather than root causes of obesity? They raise questions about societal priorities when injections drive such life-altering results. Overall, they represent unsettling yet marvelous medical advances.

Source Information

Originally published by The Week.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
Medical Insights

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.

8 min read
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
Medical Research

Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging

A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.

8 min read
Yes, GLP-1s Make You Thinner. But Do They Make You Freer?
Health & Wellness

Yes, GLP-1s Make You Thinner. But Do They Make You Freer?

While GLP-1 drugs like Ozempic and Wegovy offer significant medical benefits, their rise raises critical questions about freedom, body image, and the cultural pressure to be thinner.

8 min read

More in GLP-1 Medications

Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
GLP-1 Medications

Ozempic Era Over? BMJ Study on GLP-1 Weight Regain

The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.

3 min read
GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs
GLP-1 Medications

GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs

Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.

2 min read
Heather Gay: Sticking with GLP-1s After 25-lb Loss
GLP-1 Medications

Heather Gay: Sticking with GLP-1s After 25-lb Loss

Heather Gay, star of Real Housewives of Salt Lake City, shares her commitment to GLP-1 medications like Ozempic after shedding 25 pounds. She prioritizes how she feels over scale numbers, pairing the drug with Atkins for protein-rich nutrition. Now in her 50s, she feels healthier and more body-confident than ever.

3 min read
Share this article
  1. Home
  2. Blog
  3. Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community